

**ProteoTech to Present at  
The Alzheimer's Association International Conference 2012 (AAIC)<sup>®</sup>  
Vancouver, British Columbia, Canada, July 14-19, 2012**

**Kirkland, WA, July 14, 2012** – ProteoTech, Inc. announced today that Dr. Judy Cam, will present at The Alzheimer's Association International Conference 2012 (AAIC)<sup>®</sup> to be held in Vancouver, British Columbia, Canada, July 14-21, 2012. Dr. Cam will present on Wednesday, July 18 during the “Therapeutics/Therapeutic Strategies: Tau Directed Therapy” Symposium. Dr. Cam’s presentation is entitled:

**“Identification of Novel Small Molecules as Tau Protein Aggregation Inhibitors”**

ProteoTech has identified ten lead compounds that show robust efficacy against tau aggregation using independent *in vitro* and cell-based assays. These lead compounds are promising novel small molecule candidate therapeutics for treatment of AD and other tauopathies, and will be tested in relevant transgenic mouse models of tauopathy.

**About ProteoTech:** ProteoTech is a private research and drug development Company located in the Seattle, WA area (Kirkland, WA) and is focused on targeting misfolded protein disorders and amyloid diseases. The Company is developing small molecule drugs for the treatment of Parkinson's disease, Alzheimer's disease, type 2 diabetes, and systemic amyloid disorders (including AA, AL and TTR amyloidoses). For more information please see the Company website at [www.proteotech.com](http://www.proteotech.com).